Clinical Intelligence Platform

Pharma buried it.
We structured it.

The only platform mapping terminated rare-disease trials — with endpoint intelligence, unpublished efficacy data, and distressed asset sourcing for BD teams.

Get in Touch View Pricing
Sangamo giroctocogene · Hemophilia A Phase 3 · Bid deadline Nov 13, 2026
Sangamo ST-503 · Nav1.7 · FDA Fast Track · No buyer
Pfizer Recifercept · Achondroplasia Phase 2 · Terminated
Wilson disease TTM Phase 3 · NDA-relevant · Data holder identified
Deferiprone FA cardiac · Positive signal · Prematurely stopped
Alexion SBC-103 · Sanfilippo MPS IIIB · $85M write-down
Sangamo giroctocogene · Hemophilia A Phase 3 · Bid deadline Nov 13, 2026
Sangamo ST-503 · Nav1.7 · FDA Fast Track · No buyer
Pfizer Recifercept · Achondroplasia Phase 2 · Terminated
Wilson disease TTM Phase 3 · NDA-relevant · Data holder identified
Deferiprone FA cardiac · Positive signal · Prematurely stopped
Alexion SBC-103 · Sanfilippo MPS IIIB · $85M write-down
500+
Terminated rare-disease trials structured
87
HIGH_RISK_ABANDONED programs mapped
$12B
Estimated R&D value in tracked assets
3%
Standard finder's fee at closing
The science
didn't fail.
How it works

We find what
was buried.

01 — Source

Locate

ClinicalTrials.gov, USPTO patent records, and US Bankruptcy Court PACER dockets — ingested and risk-scored daily.

02 — Match

Connect

Map each asset to the acquirer with the strongest strategic rationale. We identify the exact data custodian — PI, trustee, or legacy file holder.

03 — Close

Earn

3% finder's fee at closing. We sign a finder's fee agreement before we make the introduction. No cure, no fee.

Pricing

Three ways to access.

Structured for Search & Evaluation, BD, and R&D teams at pharma and biotech.

Entry

Therapeutic Area Report

All terminated trials in a defined indication — endpoint definitions, enrollment data, why-stopped analysis, and data-holder contacts.

$2,500 per report
Core

Full Dataset License

500+ terminated rare-disease programs, risk-scored and model-ready in CSV and JSON. Updated quarterly.

$1,500 one-time · $500/mo
Premium

Finder's Fee Introduction

We identify the buyer, make the introduction, and earn 3% of the transaction value at closing. Agreement signed first.

3% of deal value at closing
Contact

Get in touch.

We respond to all enterprise inquiries within one business day. For active court timelines, flag your message as urgent.

Email
Response Within 1 business day
Based Latvia, EU · Serving global pharma & biotech
Fees 3% finder's fee · Agreement signed before intro